Predictors of Development of Hepatocellular Carcinoma in Non-Cirrhotic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis - A Retrospective Analysis of the National Inpatient Sample Database

作者：Samyak Dhruv, Shravya Ginnaram, Audrey Fonkam, John Boger · 发表于：Gastroenterology Research · 年份：2025 · DOI：10.14740/gr2053 · 被引用次数：2 · 研究领域：Liver Disease Diagnosis and Treatment、Drug-Induced Hepatotoxicity and Protection、Alcohol Consumption and Health Effects

Background: One-quarter of the world population is thought to have metabolic dysfunction-associated steatotic liver disease (MASLD). The incidence of metabolic dysfunction-associated steatohepatitis (MASH) and MASLD is rapidly increasing due to the ongoing global epidemic of type 2 diabetes mellitus and obesity. Hepatitis B and C have declined in incidence due to advances in prevention and treatment, yet the overall burden of hepatocellular carcinoma (HCC) continues to rise, largely driven by the growing prevalence of MASLD/MASH. MASLD/MASH is now the fastest-growing etiology of HCC in the USA, France and the UK, with an estimated annual incidence of HCC ranging from 0.5% to 2.6% in patients with MASH cirrhosis. The incidence of HCC among patients with non-cirrhotic MASLD/MASH is lower, approximately 0.1% to 1.3%. There are no screening guidelines currently for HCC in non-cirrhotic MASLD/MASH patients. Our study highlights the dire need to develop HCC predictive strategies and algorithm in this non-cirrhotic population and to move away from a cirrhotic-centered approach but rather use risk-based models. We have identified predictors of development of HCC in this patient population that can be used to develop risk-based HCC screening guidelines and models in a non-cirrhotic population with MASLD/MASH. Methods: -test and were used to establish association between two variables. The significant variables were included in the logistic regression model to identify independent asso...